Recent research published by investigators at Washington University School of Medicine in St. Louis and collaborating institutions has yielded findings on cancer risk, immune system interactions in multiple myeloma, and mechanisms behind chronic organ rejection. The studies, published in Nature Medicine, Nature Cancer, and Science Translational Medicine, respectively, present data from human cohorts and animal models.
Accelerated Biological Aging and Early-Onset Cancer Risk
A study published on June 22, 2026, in Nature Medicine provides evidence that more recently born generations show higher rates of biological aging compared to earlier cohorts. This accelerated aging was associated with an increased risk of certain cancers diagnosed at or before age 55.
Key Findings
- Data Sources: The study analyzed data from over 154,000 young adults in the UK Biobank and over 10,000 individuals in the National Institutes of Health’s All of Us Research Program in the United States.
- Measurement of Aging: Biological aging was assessed at the systemic level using clinical biomarkers (PhenoAge, Klemera-Doubal Method, metabolomic age scores) and at the organ-specific level using blood proteomic data.
Cohort Comparisons:
- In the UK cohort, individuals born between 1965 and 1974 had systemic aging levels 23% of one standard deviation higher than those born between 1950 and 1954.
- In the US cohort, participants born between 1990 and 1999 had systemic aging levels 92% of one standard deviation higher than those born between 1965 and 1969.
- Cancer Risk Association:
- Increased systemic aging was associated with an 8% increased risk of early-onset solid cancers (lung, gastrointestinal, uterine).
- Participants with the most advanced systemic aging had a 15% increased risk of early-onset solid cancers compared to those with the least advanced systemic aging.
- Organ-Specific Associations: Advanced immune system aging was linked to early-onset lung cancer. Advanced adipose tissue aging was linked to early-onset colorectal cancer.
- Genetic Controls: The association persisted after controlling for inherited genetic risks and genetic susceptibility to accelerated aging.
Significance and Context
The study is part of the Cancer Grand Challenges PROSPECT team, co-led by Yin Cao, ScD, an associate professor at Washington University School of Medicine. The researchers stated their goal is to understand how environmental factors may become biologically embedded to drive cancer risk. The findings aim to support the development of personalized prevention and early detection strategies for younger populations.
Immune Cell Atlas of Multiple Myeloma
A study published on January 9 in Nature Cancer mapped the immune cell landscape within the bone marrow of patients with multiple myeloma, a currently incurable cancer of plasma cells. The research was co-led by Washington University School of Medicine and the Multiple Myeloma Research Foundation (MMRF).
Methodology
Researchers conducted single-cell RNA sequencing on nearly 1.4 million individual plasma and immune cells from bone marrow samples of 337 newly diagnosed multiple myeloma patients.
Key Findings
- Relapse Prediction: The study identified that patients with specific immune cell types in their bone marrow at diagnosis showed a higher likelihood of early relapse after initial treatment.
- Signaling Patterns: Signaling patterns between cancer cells and immune cells were found that could promote inflammation, potentially contributing to cancer growth in aggressive disease.
- T Cell Dysfunction: A subset of T cells, typically responsible for attacking tumors, were observed to be in a dysfunctional or immunosenescent state. Instead of targeting the tumor, these cells were found to suppress immune activity against the cancer.
Clinical Implications
The researchers stated that incorporating knowledge of a patient’s bone marrow immune environment could improve upon current methods for predicting disease aggressiveness. The findings may inform the development of immune-based tests for clinicians and support the creation of new therapies that target both the tumor and the immune system.
Lymphatic Disruption and Chronic Organ Rejection
A study published in Science Translational Medicine suggests that chronic organ rejection may be linked to the disruption of lymphatic vessels in the donor organ, rather than solely being an immune system attack.
Mechanism of Rejection
The study analyzed transplanted human organs with chronic rejection and utilized mouse models of lung and heart transplantation. The research found that disrupted lymphatic drainage, occurring at the time of organ removal, can initiate fibrosis—the replacement of healthy tissue with scar tissue. The fibrosis in human tissue was linked to a buildup of a sugar molecule called hyaluronan, which accumulates due to inadequate lymphatic drainage from damaged vessels.
Critical Window: While lymphatic vessels regenerate post-transplant, the 2-3 week period of disruption is a critical window that can lead to long-term organ damage.
Interventions and Findings
In mouse models, three strategies were tested to address hyaluronan buildup and prevent fibrosis:
- Blocking the protein responsible for hyaluronan production.
- Stimulating the growth of new lymphatic vasculature.
- Blocking the signal that triggers specific cells to produce more hyaluronan.
All three interventions prevented hyaluronan accumulation and chronic fibrosis in transplanted mouse lungs. The study used genetically identical mice, demonstrating that fibrosis occurred independently of an immune response, suggesting a mechanical cause related to lymphatic vessel disruption.
Clinical Implications
One of the interventions, 4-methylumbelliferone (4-MU), which blocks hyaluronan production, is already approved in Europe and Asia for treating biliary disorders. Unlike lifelong immunosuppressive drugs, strategies targeting the lymphatic system might potentially be ceased once healthy lymphatic drainage is restored. The research team stated they are working to define the next steps to translate these findings into clinical settings.